13 states get first of its kind ICMR study on snakebites
"This study will generate real data on snakebite incidence, mortality, morbidity and socioeconomic burden of snakebite for the first time in the country to help the decision-makers in policy framing to prevent and control snakebite in India. The country still doesn't know the real snakebite burden and is hence groping in the dark when it comes to policy."
Shimla: The apex research regulator, the Indian Council of Medical Research (ICMR) conducting a first-of-its-kind study covering 13 states on incidents, mortality, morbidity and socio-economic burden of snakebites.
The apex research regulator, the Indian Council of Medical Research (ICMR) is carrying out a first-of-its-kind study on incidents of snakebite covering 13 states, including Himachal Pradesh, to gather data on mortality, morbidity and socio-economic burden.
The data will help in the framing of policies to prevent and control snakebite in India, said Dr Omesh Bharti, the national principal co-investigator for the study.
Also Read:AIIMS Bhubaneswar to conduct study to control snakebite deaths
Besides Himachal Pradesh, the study will cover Andhra Pradesh, Arunachal Pradesh, Rajasthan, Maharashtra, Kerala, Tamil Nadu, Odisha, West Bengal, Uttarakhand, Meghalaya, Mizoram and Tripura.
The national principal investigator of the study is Dr Jaideep C Menon from Preventive Cardiology & Population Health Sciences, Amrita Institute of Medical Sciences & Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala.
Dr Bharti, State Epidemiologist with the Department of Health and Family Welfare, Himachal Pradesh, said, "This study will generate real data on snakebite incidence, mortality, morbidity and socioeconomic burden of snakebite for the first time in the country to help the decision-makers in policy framing to prevent and control snakebite in India. The country still doesn't know the real snakebite burden and is hence groping in the dark when it comes to policy." An article on the study, 'ICMR task force project-survey of the incidence, mortality, morbidity and socioeconomic burden of snakebite in India: A study protocol', has been published in the international research journal Plos One on 22 August.
Dr Bharti said the survey is in progress and it takes into consideration all the geographical areas like hilly, plains, marshy, desert and coastal. It is the first such study designed for the survey of snakebite incidence in South East Asia.
Sri Lanka has done it, but they covered a population of one per cent only, whereas our study would cover a population of 6.12 per cent, he added.
Snakebite incidence study is being carried out in 31 districts in six geographical zones in the country, including West, Central, South, East, North and North-East in 13 states. Three districts of Himachal Pradesh — Kangra, Chamba and Una — are included in it.
Half of the global deaths due to venomous snakebites, estimated at 100,000 per year, occur in India.
The only representative data on snakebite available from India is the mortality data from the RGI-MDS study (Registrar General of India-1 Million Death Study) and another study on mortality from the state of Bihar. The incidence data on snakebite is available for two districts of the state of West Bengal only, he added.
The ICMR's study protocol for snakebite incidence and burden mentions that the hospital-based data on snakebite admissions and use of anti-snake venom are gross underestimates as most snakebite victims in rural India depend more on alternative treatment methods which do not get represented in national registries.
Reports suggest that only 20-30 per cent of victims of snakebite in rural India seek treatment in hospitals. Under-reporting and lack of data on incidence, mortality and socio-economic burden make it difficult to understand the true impact of a condition on the health of a population.
The study duration is for 18 months from April 2022 to October 2023.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.